User:StrictionD Review 4
It is likely that there would have been more gymnema StrictionD sylvestre hyperglycemia clinical trials if funding were available. In a recent publication in the Journal of Alternative and Complementary Medicine, researchers from Bastyr University in Washington State called research funding "critically important". Research is expensive and most funding is provided by pharmaceutical companies, but pharmaceutical companies have little interest in beneficial nutritional and botanical medicines, since they are naturally occurring and cannot be patented. Many doctors are unaware of gymnema sylvestre insulin clinical trials. Alternative and complementary medicine is still controversial, even though the effectiveness of nutritional support and botanical supplements has been proven again and again.
It takes years for mainstream medicine to accept the therapeutic properties of naturally occurring substances and some practitioners never suggest or even consider alternative or adjunctive therapies for their patients. Take for example the research conducted by Linus Pauling, a two time Nobel Prize winner, concerning vitamin C and other nutritional supplements. At the age of 41, he was diagnosed with an untreatable and fatal kidney disease. Using a low protein, salt free diet and nutritional supplements, he was able to continue to work, published several books and lived a healthy and productive life. He died in 1994 at the age of 93 from an unrelated condition.
By going outside of mainstream medicine, by using alternative therapies, he was able to live more than 50 years longer than his doctors had said that he would. His theory was always that people can live longer, healthier lives by focusing on good nutrition. Not a popular theory and still controversial to a certain extent, but Doctors of Alternative and Complementary Medicine are becoming more popular. Researchers are focusing more on alternative therapies for type II diabetes, because, according to researchers at the Institute for Pharmacology and Toxicology, "current pharmacological therapy for type 2 diabetes reduces the risk of complications, but is not able to achieve a long-lasting normalization of the metabolic disorder."